Abstract
Background
Neuroimaging studies suggest an association between apathy after deep brain stimulation (DBS) and stimulation of the ventral part of the subthalamic nucleus (STN) due to the associative fibers connected to the non-motor limbic circuits that are involved in emotion regulation and motivation. We have previously described three patients with severe apathy that could be fully treated after switching stimulation from a ventral electrode contact point to a more dorsal contact point.
Objectives
To determine whether more dorsal stimulation of the STN decreases apathy compared to standard care in a multicenter randomized controlled trial with a crossover design.
Methods
We will include 26 patients with a Starkstein Apathy Scale (SAS) score of 14 or more after subthalamic nucleus (STN) deep brain stimulation (DBS) for refractory Parkinson’s disease. This is a multicenter trial conducted in two teaching hospitals and one university medical center in the Netherlands after at least 3 months of STN DBS. Our intervention will consist of 1 month of unilateral dorsal STN stimulation compared to treatment as usual. The primary outcome is a change in SAS score following 1 month of DBS on the original contact compared to the SAS score following 1 month of DBS on the more dorsal contact. Secondary outcomes are symptom changes on the Movement Disorders Society-Unified Parkinson’s Disease Rating Scale motor part III, Montgomery-Åsberg Depression Rating Scale, 39-item Parkinson’s disease questionnaire, Parkinson’s disease impulsive-compulsive disorders questionnaire, changes in levodopa-equivalent daily dosage, apathy rated by the caregiver, and burden and quality of life of the caregiver.
Trial registration
ClinicalTrials.gov NL8279. Registered on January 10, 2020.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; van Rooijen, G. 1 ; Contarino, M. F. 2 ; van der Gaag, S. 2 ; Zutt, R. 2 ; van Asseldonk, J. T. 3 ; van den Munckhof, P. 4 ; Schuurman, P. R. 4 ; Denys, D. A. J. P. 1 ; de Bie, R. M. A. 5 1 Amsterdam UMC, Location AMC, Department of Psychiatry, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)
2 HagaZiekenhuis, the Hague, the Netherlands (GRID:grid.413591.b) (ISNI:0000 0004 0568 6689)
3 Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands (GRID:grid.416373.4)
4 Amsterdam UMC, Department of Neurosurgery, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)
5 Amsterdam UMC, Location AMC, Department of Neurology, Amsterdam, the Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)




